Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.44 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.44 |
| ▸ | HINT1 | P49773 | 3/20 | 0.43 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.42 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.42 |
| ▸ | ATIC | P31939 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14156808 | 0.91 | HPGD (0.57) | HPGDPAX8ATIC | |
| SCHEMBL25808153 | 0.85 | IMPDH2 (0.35) | HPGDIMPDH2IMPDH1HINT1PAX8 | |
| SCHEMBL14156804 | 0.79 | TAS1R3 (0.40) | TAS1R3TAS1R1 | |
| SCHEMBL22577548 | 0.78 | TYMP (0.66) | IMPDH2IMPDH1HINT1 | |
| SCHEMBL14156807 | 0.75 | ALDH1A1 (0.54) | HPGDHINT1TAS1R3TAS1R1 | |
| SCHEMBL12899836 | 0.74 | HPGD (0.63) | HPGDIMPDH2IMPDH1HINT1PAX8 | |
| SCHEMBL784543 | 0.73 | HINT1 (0.72) | HPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL14559271 | 0.73 | HINT1 (0.72) | HPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL22268191 | 0.73 | HINT1 (0.72) | HPGDIMPDH2IMPDH1HINT1 | |
| SCHEMBL19204426 | 0.73 | HINT1 (0.72) | HPGDIMPDH2IMPDH1HINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | MERCK SHARP & DOHME LLC (US) | 2023-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11685761-B2 | Cyclic di-nucleotide compounds as sting agonists | STING1, CGAS, IFNAR1 | HPGD 1650/4885IMPDH2 1125/4885IMPDH1 579/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.